Type II atrial flutter interruption with transesophageal pacing: Use of propafenone and possible change of the substrate

Flavio Doni, Elio Staffiere, Margherita Manfredi, Carlo Piemonti, Sarah Todd, Andrea Rimondini, Cesare Fiorentini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Type II atrial flutter (AFII) is an arrhythmia which usually cannot be interrupted by atrial pacing: the underlying mechanism is considered to be a leading circle without an excitable gap. We investigated whether the administration of propafenone, an antiarrhythmic drug, which primarily decreases conduction velocity, has o beneficial effect on AFII interruption using transesophageal pacing. Twelve patients with an AFII were randomized into 2 groups in which pacing was performed without treatment (group A) or two hours after the administration of 600 mg of oral propafenone (group B). Sinus rhythm was attained in 0 of 6 patients in group A and in 4 of 6 patients in group B (P <0.05). The baseline mean cycle length was the same in both groups (175 ± 7 (A) vs 168 ± 8 ms (B); it lengthened significantly after the administration of propafenone (219 ± 33 vs 168 ± 8 ms; P <0.05). Propafenone did not significantly lengthen the cycle in the two patients in whom interruption of the arrhythmia was impossible. Our data show that propafenone has a facilitating effect on atrial pacing only when it significantly prolongs the cycle length of the arrhythmia, possible expression of a conversion of AFII into type I, with an anatomical substrate and an excitable gap allowing arrhythmia capture and interruption. In the two patients in whom sinus rhythm was not restored, the absence of a direct dependence of the cycle length on the change in conduction velocity induced by propafenone may be explained by the persistence of a functionally determined circuit, resistant to atrial pacing.

Original languageEnglish
Pages (from-to)1958-1961
Number of pages4
JournalPACE - Pacing and Clinical Electrophysiology
Volume19
Issue number11 II
Publication statusPublished - 1996

Fingerprint

Propafenone
Atrial Flutter
Cardiac Arrhythmias
Anti-Arrhythmia Agents

Keywords

  • atrial flutter
  • propafenone
  • transesophageal pacing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Type II atrial flutter interruption with transesophageal pacing : Use of propafenone and possible change of the substrate. / Doni, Flavio; Staffiere, Elio; Manfredi, Margherita; Piemonti, Carlo; Todd, Sarah; Rimondini, Andrea; Fiorentini, Cesare.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 19, No. 11 II, 1996, p. 1958-1961.

Research output: Contribution to journalArticle

Doni, Flavio ; Staffiere, Elio ; Manfredi, Margherita ; Piemonti, Carlo ; Todd, Sarah ; Rimondini, Andrea ; Fiorentini, Cesare. / Type II atrial flutter interruption with transesophageal pacing : Use of propafenone and possible change of the substrate. In: PACE - Pacing and Clinical Electrophysiology. 1996 ; Vol. 19, No. 11 II. pp. 1958-1961.
@article{27ce9304564144b5ac1caf687815cd48,
title = "Type II atrial flutter interruption with transesophageal pacing: Use of propafenone and possible change of the substrate",
abstract = "Type II atrial flutter (AFII) is an arrhythmia which usually cannot be interrupted by atrial pacing: the underlying mechanism is considered to be a leading circle without an excitable gap. We investigated whether the administration of propafenone, an antiarrhythmic drug, which primarily decreases conduction velocity, has o beneficial effect on AFII interruption using transesophageal pacing. Twelve patients with an AFII were randomized into 2 groups in which pacing was performed without treatment (group A) or two hours after the administration of 600 mg of oral propafenone (group B). Sinus rhythm was attained in 0 of 6 patients in group A and in 4 of 6 patients in group B (P <0.05). The baseline mean cycle length was the same in both groups (175 ± 7 (A) vs 168 ± 8 ms (B); it lengthened significantly after the administration of propafenone (219 ± 33 vs 168 ± 8 ms; P <0.05). Propafenone did not significantly lengthen the cycle in the two patients in whom interruption of the arrhythmia was impossible. Our data show that propafenone has a facilitating effect on atrial pacing only when it significantly prolongs the cycle length of the arrhythmia, possible expression of a conversion of AFII into type I, with an anatomical substrate and an excitable gap allowing arrhythmia capture and interruption. In the two patients in whom sinus rhythm was not restored, the absence of a direct dependence of the cycle length on the change in conduction velocity induced by propafenone may be explained by the persistence of a functionally determined circuit, resistant to atrial pacing.",
keywords = "atrial flutter, propafenone, transesophageal pacing",
author = "Flavio Doni and Elio Staffiere and Margherita Manfredi and Carlo Piemonti and Sarah Todd and Andrea Rimondini and Cesare Fiorentini",
year = "1996",
language = "English",
volume = "19",
pages = "1958--1961",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "11 II",

}

TY - JOUR

T1 - Type II atrial flutter interruption with transesophageal pacing

T2 - Use of propafenone and possible change of the substrate

AU - Doni, Flavio

AU - Staffiere, Elio

AU - Manfredi, Margherita

AU - Piemonti, Carlo

AU - Todd, Sarah

AU - Rimondini, Andrea

AU - Fiorentini, Cesare

PY - 1996

Y1 - 1996

N2 - Type II atrial flutter (AFII) is an arrhythmia which usually cannot be interrupted by atrial pacing: the underlying mechanism is considered to be a leading circle without an excitable gap. We investigated whether the administration of propafenone, an antiarrhythmic drug, which primarily decreases conduction velocity, has o beneficial effect on AFII interruption using transesophageal pacing. Twelve patients with an AFII were randomized into 2 groups in which pacing was performed without treatment (group A) or two hours after the administration of 600 mg of oral propafenone (group B). Sinus rhythm was attained in 0 of 6 patients in group A and in 4 of 6 patients in group B (P <0.05). The baseline mean cycle length was the same in both groups (175 ± 7 (A) vs 168 ± 8 ms (B); it lengthened significantly after the administration of propafenone (219 ± 33 vs 168 ± 8 ms; P <0.05). Propafenone did not significantly lengthen the cycle in the two patients in whom interruption of the arrhythmia was impossible. Our data show that propafenone has a facilitating effect on atrial pacing only when it significantly prolongs the cycle length of the arrhythmia, possible expression of a conversion of AFII into type I, with an anatomical substrate and an excitable gap allowing arrhythmia capture and interruption. In the two patients in whom sinus rhythm was not restored, the absence of a direct dependence of the cycle length on the change in conduction velocity induced by propafenone may be explained by the persistence of a functionally determined circuit, resistant to atrial pacing.

AB - Type II atrial flutter (AFII) is an arrhythmia which usually cannot be interrupted by atrial pacing: the underlying mechanism is considered to be a leading circle without an excitable gap. We investigated whether the administration of propafenone, an antiarrhythmic drug, which primarily decreases conduction velocity, has o beneficial effect on AFII interruption using transesophageal pacing. Twelve patients with an AFII were randomized into 2 groups in which pacing was performed without treatment (group A) or two hours after the administration of 600 mg of oral propafenone (group B). Sinus rhythm was attained in 0 of 6 patients in group A and in 4 of 6 patients in group B (P <0.05). The baseline mean cycle length was the same in both groups (175 ± 7 (A) vs 168 ± 8 ms (B); it lengthened significantly after the administration of propafenone (219 ± 33 vs 168 ± 8 ms; P <0.05). Propafenone did not significantly lengthen the cycle in the two patients in whom interruption of the arrhythmia was impossible. Our data show that propafenone has a facilitating effect on atrial pacing only when it significantly prolongs the cycle length of the arrhythmia, possible expression of a conversion of AFII into type I, with an anatomical substrate and an excitable gap allowing arrhythmia capture and interruption. In the two patients in whom sinus rhythm was not restored, the absence of a direct dependence of the cycle length on the change in conduction velocity induced by propafenone may be explained by the persistence of a functionally determined circuit, resistant to atrial pacing.

KW - atrial flutter

KW - propafenone

KW - transesophageal pacing

UR - http://www.scopus.com/inward/record.url?scp=0029859053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029859053&partnerID=8YFLogxK

M3 - Article

C2 - 8945077

AN - SCOPUS:0029859053

VL - 19

SP - 1958

EP - 1961

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 11 II

ER -